Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Funda Meric-Bernstam

Showing results (311-320 of 686) with videos related to

Pageof 69
Sort By:
Breast Cancer Research and Treatment|August 11, 2011
Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutationsSoley Bayraktar, Angelica M Gutierrez-Barrera, Diane Liu, et al.
Annals of Surgical Oncology|July 26, 2014
Surgical patterns of care in patients with invasive breast cancer treated with neoadjuvant systemic therapy and breast magnetic resonance imaging: results of a secondary analysis of TBCRC 017Kandace P McGuire, E Shelley Hwang, Alan Cantor, et al.
Oncogene|June 10, 2021
Combined inhibition of DDR1 and CDK4/6 induces synergistic effects in ER-positive, HER2-negative breast cancer with PIK3CA/AKT1 mutationsMaryam Shariati, Kurt W Evans, Xiaofeng Zheng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2004
Anaphylactoid reactions to isosulfan blue dye during breast cancer lymphatic mapping in patients given preoperative prophylaxisChandrajit P Raut, M Denise Daley, Kelly K Hunt, et al.
American Journal of Clinical Oncology|October 4, 2005
Immediate breast reconstruction can impact postmastectomy irradiationNaomi R Schechter, Eric A Strom, George H Perkins, et al.
Annals of Surgical Oncology|April 22, 2026
ASO Visual Abstract: Implications for Sentinel Lymph Node Biopsy Omission in Patients with Early Stage Node-Negative HR+/HER2- Breast Cancer Undergoing MastectomyJennifer H Chen, Kerollos Nashat Wanis, Mahdia Rahman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2009
Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomesElizabeth A Mittendorf, Yun Wu, Maurizio Scaltriti, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 4, 2013
Differences in gene and protein expression and the effects of race/ethnicity on breast cancer subtypesMariana Chavez-Macgregor, Shuying Liu, Debora De Melo-Gagliato, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 24, 2025
Advances in Targeting HER2 across Cancer Subtypes - A Pan-tumor ApproachTaiwo Adesoye, Ecaterina E Dumbrava, Kanwal P S Raghav, et al.
Annals of Surgical Oncology|April 8, 2026
Implications for Sentinel Lymph Node Biopsy Omission in Patients with Early-Stage Node-Negative HR+/HER2- Breast Cancer Undergoing MastectomyJennifer H Chen, Kerollos Nashat Wanis, Mahdia Rahman, et al.
Pageof 69

Showing results (311-320 of 686) with videos related to

Sort By:
Pageof 69
Breast Cancer Research and Treatment|August 11, 2011
Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutationsSoley Bayraktar, Angelica M Gutierrez-Barrera, Diane Liu, et al.
Annals of Surgical Oncology|July 26, 2014
Surgical patterns of care in patients with invasive breast cancer treated with neoadjuvant systemic therapy and breast magnetic resonance imaging: results of a secondary analysis of TBCRC 017Kandace P McGuire, E Shelley Hwang, Alan Cantor, et al.
Oncogene|June 10, 2021
Combined inhibition of DDR1 and CDK4/6 induces synergistic effects in ER-positive, HER2-negative breast cancer with PIK3CA/AKT1 mutationsMaryam Shariati, Kurt W Evans, Xiaofeng Zheng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2004
Anaphylactoid reactions to isosulfan blue dye during breast cancer lymphatic mapping in patients given preoperative prophylaxisChandrajit P Raut, M Denise Daley, Kelly K Hunt, et al.
American Journal of Clinical Oncology|October 4, 2005
Immediate breast reconstruction can impact postmastectomy irradiationNaomi R Schechter, Eric A Strom, George H Perkins, et al.
Annals of Surgical Oncology|April 22, 2026
ASO Visual Abstract: Implications for Sentinel Lymph Node Biopsy Omission in Patients with Early Stage Node-Negative HR+/HER2- Breast Cancer Undergoing MastectomyJennifer H Chen, Kerollos Nashat Wanis, Mahdia Rahman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2009
Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomesElizabeth A Mittendorf, Yun Wu, Maurizio Scaltriti, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 4, 2013
Differences in gene and protein expression and the effects of race/ethnicity on breast cancer subtypesMariana Chavez-Macgregor, Shuying Liu, Debora De Melo-Gagliato, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 24, 2025
Advances in Targeting HER2 across Cancer Subtypes - A Pan-tumor ApproachTaiwo Adesoye, Ecaterina E Dumbrava, Kanwal P S Raghav, et al.
Annals of Surgical Oncology|April 8, 2026
Implications for Sentinel Lymph Node Biopsy Omission in Patients with Early-Stage Node-Negative HR+/HER2- Breast Cancer Undergoing MastectomyJennifer H Chen, Kerollos Nashat Wanis, Mahdia Rahman, et al.
Pageof 69